The Rights Issue is being carried out to strengthen the Company’s financial position, provide additional scope for the ongoing commercialization of Pepaxti in Europe, and advance the Company’s preclinical project for the indication glioblastoma to the clinical development phase.
March 13, 2026 – Oncopeptides today announces the publication of a new real-world study in the peer-reviewed European Journal of Haematology. The study, conducted at the IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy, confirms the efficacy and safety of Pepaxti (melflufen) plus dexamethasone. The heavily pretreated patients, including those refractory to novel immunotherapies, benefitted from Pepaxti’s strong efficacy, the overall response rate (ORR) was 41% with a median progression-free survival (mPFS) of 9.0 months.
March 11, 2026 – Oncopeptides CEO Sofia Heigis recently presented the company at an Aktiespararna event in Stockholm.
Released February 19, 2026
CEO Sofia Heigis
David Augustsson
Director of IR and Communications
ir@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Interim Report Q1 2026 will be published May 13, 2026
April 16, 2025
The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.
Read more
March 13, 2025
In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.
Read moreMarch 13, 2026
Read moreMarch 9, 2026
Read moreDecember 31, 2025
Oncopeptides recently announced new research demonstrating that Pepaxti (melflufen) maintains its anti-myeloma activity in patients with high-risk genetic features, including deletion 17p (del(17p)) and TP53 mutations.
Read morePress release - March 13, 2026
2026-04-13 - 2026-05-12
Other
2026-04-28
none
2026-05-13
Report
”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.
Released April 28, 2025
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025
